|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionThe BV13 monoclonal antibody reacts with mouse VE-Cadherin (CD144). VE-Cadherin is a 120 kDa member of the type II Cadherin family, characterized by the presence of 5 extracellular cadherin domains (ECD), and anchored to the actin cytoskeleton through their cytoplasmic tail. VE-Cadherin mediates homophilic adhesion between neighbouring endothelial cells and is localized within specialized structures at cell-cell contacts, called adherens junctions. VE-Cadherin is expressed constitutively throughout the entire vasculature, and is required for numerous endothelial cell functions including migration, survival, contact-dependent growth inhibition and endothelial cell assembly into tubular structures. Furthermore, it is thought that VE-Cadherin+CD45- cells from the yolk sac or aorta-gonad-mesonephros (AGM) have the potential to give rise to hematopoietic cells. Applications ReportedFor research use only, not for diagnostic or therapeutic use. This eBioBV13 (BV13) antibody has been reported for use in flow cytometric analysis, immunoprecipitation, immunoblotting (WB), and immunohistology staining of frozen tissue sections. Intravenous injection of BV13 has been shown to induce a concentration- and time-dependent increase in vascular permeability in the heart and lungs. Applications TestedThis eBioBV13 (BV13) antibody has been tested by flow cytometric analysis of bEnd.3 cells. This can be used at less than or equal to 1 μg per million cells in a 100 μl total staining volume. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. References
Corada M, Mariotti M, Thurston G, Smith K, Kunkel R, Brockhaus M, Lampugnani MG, Martin-Padura I, Stoppacciaro A, Ruco L, McDonald DM, Ward PA, Dejana E. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9815-20. (BV13, FA, IHC, PubMed) Liao F, Li Y, O'Connor W, Zanetta L, Bassi R, Santiago A, Overholser J, Hooper A, Mignatti P, Dejana E, Hicklin DJ, Bohlen P. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res. 2000 Dec 15;60(24):6805-10. (BV13, FA, PubMed) Crosby CV, Fleming PA, Argraves WS, Corada M, Zanetta L, Dejana E, Drake CJ. VE-cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood. 2005 Apr 1;105(7):2771-6. Epub 2004 Dec 16. (BV13, FA, PubMed) Related ProductsCat. 16-4301 Functional Grade Purified Rat IgG1 Isotype Control |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |